Blockade of the renin-angiotensin-aldosterone-system with either an angiotensin receptor blocker (ARB) or angiotensin-converting enzyme (ACE) inhibitor provides similar protection from cardiovascular ...
Background: The realization that angiotensin-converting enzyme (ACE) inhibitors do not provide complete blockade of angiotensin II synthesis has resulted in an increased use of combinations of ACE ...
This question came up during an evening symposium I attended at the American Society of Nephrology Renal Week last November in Philadelphia. It resulted in some heated discussion. It is necessary to ...
This drug-utilization study in a prescription database of more than 50,000 patients analyzed compliance, persistence, and switching behavior for ACE inhibitors and ARBs. Although residual confounding ...
Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting–enzyme ...
A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting–enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well ...
ACE inhibitors work by interfering with the body's renin-angiotensin-aldosterone system (RAAS). RAAS is a complex system responsible for regulating the body's blood pressure. The kidneys release an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results